References
- Di Marco A., Gaetani M., Scarpinato B. Adriamycin (NSC 123127). A new antibiotic with anti-tumor activity. Cancer Chem Rep 1969; 53: 33–37
- Benjamin R. S., Chawla S. P., Hortobagyi G. N. Adriamycin administration by continuous infusion. EORTC-symposium on continuous infusion chemotherapy, Brussels, March 1 (abstract). 1985
- Legha S. S., Benjamin R. S., Mackay B. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusions. Ann Intern Med 1982; 96: 133–139
- Oosterbaan M. JM, Dirks M. JM, Vree T. B. Clinical pharmacokinetics of adriamycin. J Drug Res 1982; 7: 1372–1378
- Oosterbaan M. JM, Dirks M. JM, Vree T. B. Pharmacokinetics of anthracyclines in dogs: Widened for structure related body distribution and reduction to their hydroxymetabolites. Pharmacol Res 1984; 1: 33–38
- Speth P. AJ. Cellular Pharmacokinetics and Pharmacodynamics of Anthracyclines in Man. Thesis. SSN Nijmegen, The Netherlands 1986
- Pilon J. W., Naeff M. SJ, Taminiau J. AJM. Door doxorubicine veroorzaakte cardiotoxiciteit bij kinderen. Ned Tijdsch Geneesk 1984; 28: 1339–1343
- Praut M. N., Richards M. JS, Chung K. J. Adriamycin cardiotoxicity in children. Cancer 1977; 39: 62–65
- Gorin A. M., Borow K. M., Goldman A. Congestive heart failures due to adriamycin cardiotoxicity. Cancer 1981; 47: 2810–2816
- Sobotka M. Personal communication 1985
- Staakvd F., Bokkerink J., Lippens R. Totally implantable systems for intravenous drug delivery. Experiences in children with cancer. Z Kinderchir 1986; 41: 39–42